Interesting facts
Interesting Facts about (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
The compound (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide belongs to a fascinating class of molecules known as indole derivatives. These compounds are renowned for their diverse biological activities and complex structures, making them a topic of significant interest in both academic research and pharmaceutical development.
Here are some notable points about this compound:
- Bioactivity Potential: Many indole derivatives exhibit promising pharmacological properties, including anti-cancer, anti-inflammatory, and microbial activities. This compound suggests potential investigations in medicinal chemistry.
- Structural Complexity: Its intricate structure incorporates multiple functional groups, which can influence reactivity and interaction patterns, providing a rich area for chemical exploration.
- Steric Considerations: The presence of chiral centers (indicated by the R and S designations) leads to stereoisomerism, which is crucial in drug design since different enantiomers can have vastly different biological effects.
- Indole Framework: The indole moiety is a key scaffold in many natural products and pharmaceutical agents, highlighting the importance of this compound in drug discovery frameworks.
- Research Applications: Investigating this compound could lead to insights into the mechanisms of action and pathways of biological responses, making it a valuable subject for research studies.
Overall, (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide presents a compelling profile for scientists interested in the interplay of chemistry and biology. Its diverse potential and structural intricacies warrant further exploration in various fields, including drug development and synthetic chemistry.
Synonyms
methysergide
Sansert
Methysergid
361-37-5
Desernil
Deseryl
Desernyl
Desril
Deseril
Metisergide [DCIT]
1-Methylmethylergonovine
Methysergidum
Metisergide
Metisergido
Methysergidum [INN-Latin]
Metisergido [INN-Spanish]
UML 491
UML-491
Methysergide [USAN:INN:BAN]
HSDB 3237
EINECS 206-644-0
Methyllysergic acid butanolamide
XZA9HY6Z98
BRN 0765985
N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide
DTXSID2023307
METHYSERGIDE [MI]
METHYSERGIDE [INN]
METHYSERGIDE [HSDB]
METHYSERGIDE [USAN]
METHYSERGIDE [VANDF]
CHEMBL1065
1-Methyl-D-lysergic acid butanolamide
METHYSERGIDE [MART.]
METHYSERGIDE [WHO-DD]
DTXCID703307
Lysergamide, N-(1-(hydroxymethyl)propyl)-1-methyl-, D-
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
Dimethylergometrin
Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta)-
Ergoline-8beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-
Methylmethylergonovine
NCGC00024027-05
1-Methyllysergic acid butanolamide
(+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide
1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide
Methysergidum (INN-Latin)
Metisergido (INN-Spanish)
Ergoline-8-beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-
METHYSERGIDE (MART.)
9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
(+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide
Desernil Sandoz
MLS000069364
(8alpha)-N-[(2S)-1-hydroxybutan-2-yl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
(8beta)-9,10-Didehydro-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8-carboxamide
(4R,7R)-N-[(2S)-1-hydroxybutan-2-yl]-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
(6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS-361-37-5
SMR000058483
Methysergide (USAN/INN)
UNII-XZA9HY6Z98
DAsernil Sandoz
DAsernil-Sandoz
(4R,7R)-N-((2S)-1-hydroxybutan-2-yl)-6,11-dimethyl-6,11-diazatetracyclo(7.6.1.0^(2,7).0^(12,16))hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
(4R,7R)-N-(1-hydroxybutan-2-yl)-6,11-dimethyl-6,11-diazatetracyclo(7.6.1.02,7.012,16)hexadeca-1(15),2,9,12(16),13-pentaene-4-carboxamide
(4R,7R)-N-(1-hydroxybutan-2-yl)-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2,9,12(16),13-pentaene-4-carboxamide
(6aR,9R)-N-((1S)-1-(hydroxymethyl)propyl)-4,7-dimethyl-6,6a,8,9-tetrahydroindolo(4,3-fg)quinoline-9-carboxamide
Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta(S))-
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid
Biomol-NT_000155
Lopac0_000863
SCHEMBL41843
GTPL134
BPBio1_000486
(8beta)-9,10-Didehydro-N-
BDBM30708
CHEBI:92629
cid_5281073
N02CA04
(8R)-N-(1-hydroxymethyl(propyl))-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
(8R)-N-[1-hydroxymethyl(propyl)]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
KPJZHOPZRAFDTN-ZRGWGRIASA-N
HMS2090P04
Tox21_110895
BDBM50031942
Tox21_110895_1
CCG-204945
FM31590
SDCCGSBI-0050838.P003
(8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
NCGC00024027-04
NCGC00024027-06
NCGC00024027-07
NCGC00024027-08
NCGC00024027-09
NCGC00024027-13
SBI-0050838.P002
NS00001621
C07199
D02357
AB00513725-14
AB00513725_15
Q424442
ERGOMETRINE MALEATE IMPURITY G [EP IMPURITY]
BRD-K35941380-001-01-7
BRD-K35941380-050-17-0
BRD-K35941380-050-27-9
N-(1-(HYDROXYMETHYL)PROPYL)-1-METHYLLYSERGAMIDE
N-(1-(HYDROXYMETHYL)PROPYL)-1-METHYL-D-LYSERGAMIDE
1-METHYL-D-LYSERGIC ACID (+)-1-HYDROXY-2-BUTYLAMIDE
(8beta)-N-[(2S)-1-Hydroxybutan-2-yl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide
(6aR,9R)-4,6a,7-Trimethyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (1-hydroxymethyl-propyl)-amide
(6aR,9R)-4,7-Dimethyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-1-hydroxymethyl-propyl)-amide
(6aR,9R)-4,7-dimethyl-N-[(1S)-1-methylolpropyl]-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide;maleate
(6aR,9R)-4,7-dimethyl-N-[(1S)-1-methylolpropyl]-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide;maleic acid
(6aR,9R)-4,7-dimethyl-N-[(2S)-1-oxidanylbutan-2-yl]-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide;(Z)-but-2-enedioic acid
(6aR,9R)-4-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (1-hydroxymethyl-propyl)-amide
(6aR,9R)-5,7-Dimethyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid diethylamide
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide;(Z)-2-butenedioic acid
(methylsergide)4,7-Dimethyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (1-hydroxymethyl-propyl)-amide
206-644-0
4,7-Dimethyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (1-hydroxymethyl-propyl)-amide
H8J
Solubility of (6aR,9R)-N-[(1S)-1-(hydroxymethyl)propyl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
The solubility of this compound is an essential aspect to consider for both its practical applications and its pharmacological profiles. It is particularly relevant to how effectively the compound can be dissolved in various solvents, which can impact its behavior in biological systems. Here are some key points regarding its solubility:
Overall, understanding the solubility characteristics of this specific compound could facilitate better design strategies in medicinal chemistry, enabling enhanced drug formulation capabilities and optimization in biological activity.